<span item_type="fundamental" item_id="60db90bef89d750181aaecf709be39cd" counter_id="ST/US/IONS" env="prod"></span><span item_type="announcement" item_id="543933301611435777" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 452 M, beating the estimate of USD 298.99 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.7, beating the estimate of USD -0.0908.</p><p>EBIT: As of FY2025 Q2, the actual value is USD 140 M, beating the estimate of USD -14.86 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>TRYNGOLZA Sales</strong>: $19 million in net product sales in the second quarter of 2025 and $26 million in the first half of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li><li><strong>Total Revenue</strong>: $452 million for the second quarter of 2025, compared to $225 million in the same period of 2024; $584 million for the first half of 2025, compared to $345 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Expenses</strong>: $312 million for the second quarter of 2025, compared to $291 million in the same period of 2024; $591 million for the first half of 2025, compared to $560 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li><li><strong>Income (Loss) from Operations</strong>: $140 million for the second quarter of 2025, compared to -$66 million in the same period of 2024; -$7 million for the first half of 2025, compared to -$215 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li><li><strong>Net Income (Loss)</strong>: $124 million for the second quarter of 2025, compared to -$66 million in the same period of 2024; -$23 million for the first half of 2025, compared to -$209 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Cash, Cash Equivalents, and Short-term Investments</strong>: $2.3 billion as of June 30, 2025, consistent with December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Royalty Revenue</strong>: $70 million for the second quarter of 2025, compared to $64 million in the same period of 2024; $134 million for the first half of 2025, compared to $113 million in the same period of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Ionis Pharmaceuticals, Inc. has increased its 2025 financial guidance, projecting total revenue between $825-850 million, up from the previous guidance of $725-750 million, driven by strong performance and improved outlook. TRYNGOLZA product sales are expected to reach $75-80 million. The company anticipates achieving sustained growth and positive cash flow in the next few years, supported by multiple independent launches and increasing royalty revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm"></span></li></ul>

Ionis Pharma | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 452 M